Serum level of AGE/RAGE as a potential biomarker for acute stroke

Abstract

A secreted isoform of receptor for advanced glycation end products (sRAGE) involves sRAGE and endogenous sRAGE (esRAGE). Pentosidine is one of an advanced glycation end product (AGE). Few studies addressed the pivotal roles of the AGEs-RAGE system in acute stroke patients. We measured plasma sRAGE, esRAGE, and pentosidine levels associated with clinical features in acute stroke. The low level of sRAGE was associated with severe leukoaraiosis, high NIHH scores on admission, and cigarette smoking. Significant correlation was observed between the levels of serum sRAGE and esRAGE (R=0.85). Both of which had significant reverse association with estimated glomerular filtration rate. Higher levels of serum pentosidine compared with normal controls were demonstrated in patients with acute stroke. Decreased levels of sRAGE as well as esRAGE in patients with brain hemorrhage were examined 3 days after the onset, however, they increased 14 days after. These findings suggested that sRAGE as well as esRAGE would contribute to the pathogenesis of the onset of brain hemorrhage, and that the serum levels of pentosidine could be a marker of future stroke.